Rallybio Corporation (RLYB)
NASDAQ · Manufacturing · Pharmaceutical preparations
RLYB price, last 12 months
Key stats
- Previous close
- $16.61
- Open
- $16.80
- Day range
- $16.63 – $17.07
- 52-week range
- $3.67 – $17.57
- Volume
- 3.7K
- Avg volume (20 days)
- 10.2K
- Market cap
- $88.3M
Performance
Technicals and fundamentals
About Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $88.3M